January 24, 2026
RA Jainee
Mirae Asset Nifty 500 Healthcare ETF | Growth
📌 Fund Snapshot & Key Details
| Particulars | Details |
|---|---|
| Fund House | Mirae Asset Mutual Fund |
| Scheme Type | Open-ended |
| Category | Equity: Sectoral – Healthcare / Pharma |
| Benchmark | Nifty 500 Healthcare TRI |
| NFO Opens | 27 January 2026 |
| NFO Closes | 06 February 2026 |
| Plan / Option | Growth |
| Minimum Investment (Rs.) | 5,000 |
| Exit Load | 0 |
| Lock-in Period | NA |
| Riskometer | Very High |
| Registrar | KFin Technologies Ltd. |
⚖️ Sahifund NFO Review
Mirae Asset Nifty 500 Healthcare ETF | Growth
PLUS
• Broad-based exposure to India’s healthcare ecosystem (pharma, hospitals, diagnostics, healthcare services)
• Lower market correlation and beta than NIFTY 50, aiding diversification
• Rule-based, passive sector exposure without stock-selection risk
• Long-term structural growth drivers: ageing population, healthcare penetration, exports
• No exit load; suitable for long-term holding
MINUS
• High sector valuations (P/E ~38) limit near-term upside
• Sectoral ETF — performance can be cyclical and phase-dependent
• Dividend yield is low, offering limited income cushion
• Not suitable as a standalone core equity allocation
• Higher volatility than diversified index funds
Sahifund View
A focused healthcare sector play best suited as a satellite allocation for investors with long-term conviction and high risk appetite.
👉 Apply Online | Ask Us MF Queries |
⏱️ Last Updated: 27 January 2026, 10.00 AM
📊 Sahifund Interpretation of the Benchmark – Nifty 500 Healthcare TRI
The Nifty 500 Healthcare TRI tracks the top 50 healthcare companies from the Nifty 500 universe, selected on free-float market capitalisation and capped periodically to manage concentration risk.
Historically, the index has delivered steady long-term compounding with lower correlation to broader markets, though returns tend to lag during momentum-driven rallies and outperform during defensive or earnings-quality phases.
Sahifund Insight:
This benchmark rewards patience. Returns are driven more by earnings durability and innovation cycles than short-term market sentiment.
👤 Sahifund Interpretation of Fund Managers & Their Performance
Ekta Gala
Experience across index and ETF products at Mirae Asset and ICICI Prudential AMC. Past ETF performance shows close-to-benchmark delivery, which is appropriate for a passive mandate.
Ritesh Patel
Brings strong compliance, governance, and operational expertise. In ETF structures, his role supports tracking efficiency and execution discipline rather than alpha generation.
Sahifund Assessment:
For this ETF, outcomes will depend primarily on sector performance and tracking error control, not fund-manager discretion.
🎯 Suitable for Which Investors?
Suitable if you:
• Believe in long-term healthcare and pharma growth
• Want sector diversification within an equity portfolio
• Have a 5–7 year or longer horizon
• Can tolerate interim underperformance
Avoid if you:
• Prefer diversified or low-volatility funds
• Are investing for the short term
• Are uncomfortable with sectoral cycles
• Expect steady income or quick gains
❓ Should You Invest in This NFO?
Yes, selectively.
This NFO fits well as a satellite sector allocation for long-term investors seeking exposure to healthcare’s structural growth. It should complement, not replace, diversified equity funds.
Final Word:
A defensive growth theme with long-term merit — rewarding over time, but demanding patience through valuation cycles.
⚠️ Disclaimer
Mutual fund investments are subject to market risks. Read all scheme-related documents carefully.
Quicklinks